Clinical Trial

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

Study acronym: CAREMM-004
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of autologous stem cell transplantation combined with BCMA CAR-T therapy followed by GPRC5D/CD3 bispecific antibody maintenance in transplant-eligible patients with primary plasma cell leukemia.
Trial Details
NCT Number NCT07106684
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Multiple Myeloma, Plasma Cell Leukemia
Enrollment 20 participants
Start Date 2025-08-10
Primary Completion 2027-08-01 (estimated)
Study Completion 2029-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-06